You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
九芝堂(000989.SZ):北京美科的缺血耐受人同種異體骨髓間充質幹細胞治療缺血性腦卒中的臨牀試驗順利開展
格隆匯 06-01 15:08

格隆匯6月1日丨九芝堂(000989.SZ)近日接受機構調研,交流環節中,就“公司幹細胞研發的進度如何,什麼時間可以成藥?”,公司回覆稱,北京美科的缺血耐受人同種異體骨髓間充質幹細胞治療缺血性腦卒中的臨牀試驗順利開展,截至2022年末,北京天壇醫院成功完成15例入組和給藥,無藥物相關不良事件報吿,臨牀試驗效果良好;已經提交治療呼吸系統罕見病的Pre-IND申請;治療兒童孤獨症、慢性缺血性腦卒中等多個適應症的臨牀前研究也取得顯著藥效學結果,進展順利。由於藥物研發的特殊性,從臨牀試驗到投產上市的週期長、環節多,易受到諸多不可預測的因素影響,臨牀試驗進度及結果、未來產品市場競爭形勢均存在諸多不確定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account